Cdc25A regulates matrix metalloprotease 1 through Foxo1 and mediates metastasis of breast cancer cells

Molecular and Cellular Biology

Volumn 31, Issue 16, 2011, Pages 3457-3471

  Feng, Xiaoling ^b,c   Wu, Zhaojia ^a   Wu, Yongsheng ^b,c   Hankey, William ^b   Prior, Thomas W ^b   Li, Lei ^a,b   Ganju, Ramesh K ^b   Shen, Rulong ^b   Zou, Xianghong ^a,b,c  

^a CAPITAL NORMAL UNIVERSITY   (China)

^b OHIO STATE UNIVERSITY   (United States)

^c OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CDC25A PROTEIN; CDC25A PROTEIN ANTIBODY; CYCLIN DEPENDENT KINASE 2; INTERSTITIAL COLLAGENASE; PROTEIN ANTIBODY; PROTEIN TYROSINE PHOSPHATASE; TRANSCRIPTION FACTOR FKHR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BREAST CANCER; BREAST METASTASIS; CANCER CELL; CANCER PATIENT; CELL PROLIFERATION; CONTROLLED STUDY; DRUG INHIBITION; FEMALE; GENE OVEREXPRESSION; GENE TARGETING; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MEDIATOR; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN FUNCTION; PROTEIN STABILITY; RECEPTOR DOWN REGULATION; TRANSCRIPTION REGULATION; TUMOR XENOGRAFT;

ANIMALS; BREAST NEOPLASMS; CDC25 PHOSPHATASES; CELL LINE, TUMOR; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MATRIX METALLOPROTEINASE 1; MICE; NEOPLASM METASTASIS; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 79961137121     PISSN: 02707306     EISSN: 10985549     Source Type: Journal    
DOI: 10.1128/MCB.05523-11     Document Type: Article

References (57)

1. Abedin, M. J., D. Wang, M. A. McDonnell, U. Lehmann, and A. Kelekar. 2007. Autophagy delays apoptotic death in breast cancer cells following DNA damage. Cell Death Differ. 14:500-510.
2. Arden, K. C. 2007. FoxOs in tumor suppression and stem cell maintenance. Cell 128:235-237.
3. Bachmeier, B. E., et al. 2008. Curcumin downregulates the inflammatory cytokines CXCL1 and -2 in breast cancer cells via NFkappaB. Carcinogenesis 29:779-789.
4. Blomberg, I., and I. Hoffmann. 1999. Ectopic expression of Cdc25A accelerates the G(1)/S transition and leads to premature activation of cyclin Eand cyclin A-dependent kinases. Mol. Cell. Biol. 19:6183-6194.
5. Boutros, R., V. Lobjois, and B. Ducommun. 2007. CDC25 phosphatases in cancer cells: key players? Good targets? Nat. Rev. Cancer 7:495-507.
6. Bradbury, P. A., et al. 2009. Matrix metalloproteinase 1, 3 and 12 polymorphisms and esophageal adenocarcinoma risk and prognosis. Carcinogenesis 30:793-798.
7. Busino, L., et al. 2003. Degradation of Cdc25A by beta-TrCP during S phase and in response to DNA damage. Nature 426:87-91.
8. Cangi, M. G., et al. 2000. Role of the Cdc25A phosphatase in human breast cancer. J. Clin. Invest. 106:753-761.
9. Cao, J., et al. 2008. Membrane type 1 matrix metalloproteinase induces epithelial-to-mesenchymal transition in prostate cancer. J. Biol. Chem. 283: 6232-6240.
10. Castrellon, A. B., and S. Gluck. 2008. Chemoprevention of breast cancer. Expert Rev. Anticancer Ther. 8:443-452.
11. Chen, M. S., J. Hurov, L. S. White, T. Woodford-Thomas, and H. Piwnica-Worms. 2001. Absence of apparent phenotype in mice lacking Cdc25C protein phosphatase. Mol. Cell. Biol. 21:3853-3861.
12. Chen, M. S., C. E. Ryan, and H. Piwnica-Worms. 2003. Chk1 kinase negatively regulates mitotic function of Cdc25A phosphatase through 14-3-3 binding. Mol. Cell. Biol. 23:7488-7497.
13. Cheng, S., et al. 2008. High MMP-1 mRNA expression is a risk factor for disease-free and overall survivals in patients with invasive breast carcinoma. J. Surg. Res. 146:104-109.
14. Chiang, A. C., and J. Massague. 2008. Molecular basis of metastasis. N. Engl. J. Med. 359:2814-2823.
15. Chiu, Y. T., et al. 2009. CDC25A functions as a novel Ar corepressor in prostate cancer cells. J. Mol. Biol. 385:446-456.
16. Culhane, A. C., and J. Quackenbush. 2009. Confounding effects in "a sixgene signature predicting breast cancer lung metastasis". Cancer Res. 69: 7480-7485.
17. Dhawan, P., and A. Richmond. 2002. A novel NF-kappa B-inducing kinase-MAPK signaling pathway up-regulates NF-kappa B activity in melanoma cells. J. Biol. Chem. 277:7920-7928.
18. Ferguson, A. M., L. S. White, P. J. Donovan, and H. Piwnica-Worms. 2005. Normal cell cycle and checkpoint responses in mice and cells lacking Cdc25B and Cdc25C protein phosphatases. Mol. Cell. Biol. 25:2853-2860.
19. Galaktionov, K., and D. Beach. 1991. Specific activation of cdc25 tyrosine phosphatases by B-type cyclins: evidence for multiple roles of mitotic cyclins. Cell 67:1181-1194.
20. Galaktionov, K., et al. 1995. CDC25 phosphatases as potential human oncogenes. Science 269:1575-1577.
21. Gasparotto, D., et al. 1997. Overexpression of CDC25A and CDC25B in head and neck cancers. Cancer Res. 57:2366-2368.
22. Greenberg, P. A., et al. 1996. Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J. Clin. Oncol. 14:2197-2205.
23. Huang, H., K. M. Regan, Z. Lou, J. Chen, and D. J. Tindall. 2006. CDK2-dependent phosphorylation of FOXO1 as an apoptotic response to DNA damage. Science 314:294-297.
24. Huang, H., and D. J. Tindall. 2007. Dynamic FoxO transcription factors. J. Cell Sci. 120:2479-2487.
25. Ito, Y., et al. 2004. Expression of cdc25A and cdc25B phosphatase in breast carcinoma. Breast Cancer 11:295-300.
26. Jeffery, N., M. H. McLean, E. M. El-Omar, and G. I. Murray. 2009. The matrix metalloproteinase/tissue inhibitor of matrix metalloproteinase profile in colorectal polyp cancers. Histopathology 54:820-828.
27. Jinno, S., et al. 1994. Cdc25A is a novel phosphatase functioning early in the cell cycle. EMBO J. 13:1549-1556.
28. Kang, T., et al. 2008. GSK-3 beta targets Cdc25A for ubiquitin-mediated proteolysis, and GSK-3 beta inactivation correlates with Cdc25A overproduction in human cancers. Cancer Cell 13:36-47.
29. Karagoz, I. D., et al. 2010. CDC 25A gene 263C/T, -350C/T, and -51C/G polymorphisms in breast carcinoma. Tumour Biol. 31:597-604.
30. Kennedy, D. A., T. Lee, and D. Seely. 2009. A comparative review of thermography as a breast cancer screening technique. Integr. Cancer Ther. 8:9-16.
31. Kim, M. Y., et al. 2009. Tumor self-seeding by circulating cancer cells. Cell 139:1315-1326.
32. Krtolica, A., and J. W. Ludlow. 1996. Hypoxia arrests ovarian carcinoma cell cycle progression, but invasion is unaffected. Cancer Res. 56:1168-1173.
33. Langley, R. R., and I. J. Fidler. 2007. Tumor cell-organ microenvironment interactions in the pathogenesis of cancer metastasis. Endocr. Rev. 28:297-321.
34. Lincoln, A. J., et al. 2002. Cdc25b phosphatase is required for resumption of meiosis during oocyte maturation. Nat. Genet. 30:446-449.
35. Ma, L., J. Teruya-Feldstein, and R. A. Weinberg. 2007. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature 449:682-688.
36. Minn, A. J., et al. 2005. Distinct organ-specific metastatic potential of individual breast cancer cells and primary tumors. J. Clin. Invest. 115:44-55.
37. Nelson, M. H., and C. R. Dolder. 2007. A review of lapatinib ditosylate in the treatment of refractory or advanced breast cancer. Ther. Clin. Risk Manag. 3:665-673.
38. Nilsson, I., and I. Hoffmann. 2000. Cell cycle regulation by the Cdc25 phosphatase family. Prog. Cell Cycle Res. 4:107-114.
39. Ouyang, W., O. Beckett, R. A. Flavell, and M. O. Li. 2009. An essential role of the Forkhead-box transcription factor Foxo1 in control of T cell homeostasis and tolerance. Immunity 30:358-371.
40. Poola, I., et al. 2005. Identification of MMP-1 as a putative breast cancer predictive marker by global gene expression analysis. Nat. Med. 11:481-483.
41. Rahman, K. M., et al. 2006. Therapeutic intervention of experimental breast cancer bone metastasis by indole-3-carbinol in SCID-human mouse model. Mol. Cancer Ther. 5:2747-2756.
42. Ray, D., et al. 2005. Transforming growth factor beta facilitates beta-TrCPmediated degradation of Cdc25A in a Smad3-dependent manner. Mol. Cell. Biol. 25:3338-3347.
43. Ray, D., et al. 2007. Hemizygous disruption of Cdc25A inhibits cellular transformation and mammary tumorigenesis in mice. Cancer Res. 67:6605-6611.
44. Rudolph, J. 2007. Inhibiting transient protein-protein interactions: lessons from the Cdc25 protein tyrosine phosphatases. Nat. Rev. Cancer 7:202-211.
45. Sauter, W., et al. 2008. Matrix metalloproteinase 1 (MMP1) is associated with early-onset lung cancer. Cancer Epidemiol. Biomarkers Prev. 17:1127-1135.
46. Trivedi, V., et al. 2009. Platelet matrix metalloprotease-1 mediates thrombogenesis by activating PAR1 at a cryptic ligand site. Cell 137:332-343.
47. van der Horst, A., and B. M. Burgering. 2007. Stressing the role of FoxO proteins in lifespan and disease. Nat. Rev. Mol. Cell Biol. 8:440-450.
48. Wang, X. Q., et al. 2008. Aberrant Polo-like kinase 1-Cdc25A pathway in metastatic hepatocellular carcinoma. Clin. Cancer Res. 14:6813-6820.
49. Wen, R., et al. 2006. Essential role of phospholipase C gamma 2 in early B-cell development and Myc-mediated lymphomagenesis. Mol. Cell. Biol. 26:9364-9376.
50. Wu, W., Y. H. Fan, B. L. Kemp, G. Walsh, and L. Mao. 1998. Overexpression of cdc25A and cdc25B is frequent in primary non-small cell lung cancer but is not associated with overexpression of c-myc. Cancer Res. 58:4082-4085.
51. Wu, Y., et al. 2010. A novel mechanism of indole-3-carbinol effects on breast carcinogenesis involves induction of Cdc25A degradation. Cancer Prev. Res. 3:818-828.
52. Yamagata, K., et al. 2008. Arginine methylation of FOXO transcription factors inhibits their phosphorylation by Akt. Mol. Cell 32:221-231.
53. Yang, E., et al. 2009. Blockade of PAR1 signaling with cell-penetrating pepducins inhibits Akt survival pathways in breast cancer cells and suppresses tumor survival and metastasis. Cancer Res. 69:6223-6231.
54. Yuan, Z., et al. 2008. Activation of FOXO1 by Cdk1 in cycling cells and postmitotic neurons. Science 319:1665-1668.
55. Zhao, H., J. L. Watkins, and H. Piwnica-Worms. 2002. Disruption of the checkpoint kinase 1/cell division cycle 25A pathway abrogates ionizing radiation-induced S and G2 checkpoints. Proc. Natl. Acad. Sci. U. S. A. 99: 14795-14800.
56. Zou, X., et al. 2002. Cdk4 disruption renders primary mouse cells resistant to oncogenic transformation, leading to Arf/p53-independent senescence. Genes Dev. 16:2923-2934.
57. Zou, X., et al. 2001. The cell cycle-regulatory CDC25A phosphatase inhibits apoptosis signal-regulating kinase 1. Mol. Cell. Biol. 21:4818-4828.